Menu

CRISPR to Debut in Clinical Trials

The first industry-sponsored CRISPR therapy is slated to be tested in humans in 2018.

Dec 14, 2017
Diana Kwon

ISTOCK, BUBAONELast Thursday (December 7), CRISPR Therapeutics submitted an application to European regulatory authorities seeking permission to begin clinical trials for CTX001, an investigational CRISPR treatment for patients with sickle cell disease and β thalassemia.

CRISPR Therapeutics, the company cofounded by Emmanuel Charpentier—one of the developers of CRISPR gene editing technology—plans to start a Europe-based Phase 1/2 trial for patients with β thalassemia in 2018. “I think it’s a momentous occasion for us, but also for the field in general,” Samarth Kulkarni, CEO of the company, tells Wired. “Just three years ago we were talking about CRISPR-based treatments as sci-fi fantasy, but here we are.”

The firm also plans to apply for US Food and Drug Administration approval to use the treatment for sickle cell disease early next year.

Patients with sickle cell disease and β thalassemia possess mutations in a gene that produces a subunit of hemoglobin, an oxygen-transporting protein in the blood. CTX001 works by cleaving BCL11A, a gene that represses the production of fetal hemoglobin, which is only produced early in life.

According to preclinical data presented by the company last Sunday (December 10) at the American Society of Hematology (ASH) meeting in Atlanta, cell- and animal-based experiments show that CTX001 has high editing efficiency and no detectable off-target effects.

“It is important that they do this very carefully,” Stuart Orkin, a hematologist-oncologist at Boston Children’s Hospital, tells Chemical & Engineering News. “Because if there is a mistake or bad effect [from CRISPR], it will have repercussions beyond a single patient.”

Other companies are working on their own versions of this therapy. Intellia Therapeutics also announced promising data for its BCL11A-based CRISPR treatment at ASH earlier this week, and Sangamo Therapeutics is targeting the gene with zinc finger nucleases, an older gene editing technique.

Clarification (December 14): The subheading of this article was changed to clarify that the therapy is entering clinical trials, rather than entering the market.

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.